CYP

1.89%

27.0¢ cynata therapeutics limited

Ann: Investor Presentation, page-525

First 525 Last

Share
Profile

Follow
JB1975

1,995 Posts.

1171

18/06/24

23:56

Post #: 74379579
Share

Originally posted by Bazsa: ↑

First I ask holders here , what is the outcome for CYP if MSB gains approval or not? My view is that CYPs future lies in some ones success of getting something across the line. CYP would then be able to work in reproducing the product at much larger scale and cheaper. When someone has a good potency assay you should be able to tweak the process , possibly from original cell source and effectively match the product.

It seems that @truss20 may have missed some of the progress MSB have made over the last 4 years.

"Essentially, MSB were unable to get approval of Rem-L in paediatric Gvhd. This was/is due to the current clinical trial data being not being adequately controlled and related potency assays were not sufficiently related to the mechanism of action."

This would be a good summary of facts recorded in CRL 1
We have moved way past those dark times, as we had the first Type A meeting, the results, we had to fix the potency assays before progressing clinical trials. It was not a clinical hold as the FDA continued to allow us to use the cells on compassionate grounds. We know just over 70 adults had been given the treatment after CRL 1

More importantly is the outcomes of the COMPLETE RESPONSE of BLA 2 . We had some good outcomes, the FDA did not question efficacy of 001. It has been deemed successful and well controlled. Matching patients and then following them is actually better than a RCT because it takes into account current standard of care. To confirm this a statement was released by a very high US expert " the outcomes in children are compelling "

As all know we still got a CRL . The reason given. We ( FDA) can not be assured that current stock would be as same that was used in 001. More confirmation that 001 has been found good. Please provide more data to show that current stock is the same as used in 001. After the 2 type A meeting the FDA concluded that they could not approve due to what they considered lack of having a adequately standardised product SI points to the regulation. This is the opinion of the FDA.

So how well was the product standardised in 001?
Out of 11 lots used in 001 just 2 had minimal impact on results on entry level data from patients in 001 but wouldn't it be likely that without treatment those results would have been negative.

Could it be considered the product was standardised appropriately for a P3 trial, FDA may have even made a similar mistake to what JB has.

Next , why would SI miss represent statements from the FDA ?
Sue is keeping a eye on things. FDA may make public comment to counter false or misleading claims.

Expand

"FDA may have even made a similar mistake to what JB has"

What mistake?

CYP Price at posting: 30.5¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

ITM

Fast-track assaying yields 182 g/t gold for iTech at new NT play

Climate change to drive market trends to the moon

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

LLL

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

RHI

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

TVN

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

KGL

KGL sniffs 19% Cu from drilling at Rockface play in NT

STN

Saturn’s stars have aligned for the gold explorer’s Apollo Project

There are more pages in this discussion • 85 more messages in this thread...

First 525 Last

Add CYP (ASX) to my watchlist

(20min delay)
Last 27.0¢		Change 0.005(1.89%)		Mkt cap ! $48.50M

Open	High	Low	Value	Volume
27.0¢	27.0¢	27.0¢	$4	13

Buyers (Bids)

No.	Vol.	Price($)
1	18895	26.5¢

Sellers (Offers)

Price($)	Vol.	No.
28.5¢	5700	1

View Market Depth

No.	Vol.	Price($)
1	18895	0.265
1	77000	0.260
3	17000	0.250
1	8000	0.245
3	105225	0.240

Price($)	Vol.	No.
0.290	4998	1
0.300	15000	1
0.305	50000	1
0.310	16591	3
0.340	100000	1

Last trade - 13.43pm 05/07/2024 (20 minute delay)

CYP (ASX) Chart

Ann: Investor Presentation, page-525

Fast-track assaying yields 182 g/t gold for iTech at new NT play

Climate change to drive market trends to the moon

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

KGL sniffs 19% Cu from drilling at Rockface play in NT

Saturn’s stars have aligned for the gold explorer’s Apollo Project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Investor Presentation, page-525

Top Stories

Fast-track assaying yields 182 g/t gold for iTech at new NT play

Climate change to drive market trends to the moon

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

KGL sniffs 19% Cu from drilling at Rockface play in NT

Saturn’s stars have aligned for the gold explorer’s Apollo Project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News